Related Experiment Video
Updated: Jul 5, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Dopamine agonists in Parkinson's disease.
Mitsutoshi Yamamoto1, Anthony H V Schapira
1Department of Neurology, Kagawa, Prefectural Central Hospital, Takamatsu, Japan.
Expert Review of Neurotherapeutics
|April 18, 2008
Summary
Dopamine agonists effectively treat Parkinson's disease (PD) motor symptoms and may slow disease progression. Non-ergot options offer a good safety profile, though side effects can occur.
Area of Science:
- Neurology
- Pharmacology
Background:
- Dopamine agonists are key for Parkinson's disease (PD) symptomatic management.
- They offer motor symptom control with low motor complication risk in monotherapy.
- As adjuncts to levodopa, they enhance motor control and reduce levodopa dependency.
Purpose of the Study:
- To review the role and efficacy of dopamine agonists in Parkinson's disease management.
- To highlight the benefits of non-ergot dopamine agonists and their safety profile.
- To discuss their impact on motor and non-motor symptoms, and disease progression.
Main Methods:
- Review of established literature on dopamine agonist use in Parkinson's disease.
- Analysis of clinical trial data regarding efficacy and safety.
- Examination of neuroprotective effects observed through imaging studies.
Main Results:
- Dopamine agonists provide effective motor symptom control in PD.
- Non-ergot agonists generally have favorable safety profiles, with potential for sedation and cognitive/behavioral side effects.
- Pramipexole shows efficacy in treating depressive symptoms in PD patients.
- Ropinirole and pramipexole demonstrated a reduced rate of nigrostriatal degeneration compared to levodopa.
Conclusions:
- Dopamine agonists are integral to the Parkinson's disease treatment algorithm.
- They offer multifaceted benefits including motor control, potential neuroprotection, and management of non-motor symptoms.
- Careful patient selection and monitoring are necessary to manage potential side effects.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...